Market Overview:
The global generic and biosimilar pharmaceuticals market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for affordable and high-quality drugs, rising prevalence of chronic diseases, and growing number of patent expiries. The monoclonal antibodies segment is expected to account for the largest share of the global generic and biosimilar pharmaceuticals market in 2018. This segment is projected to grow at a CAGR of 11.5% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to the increasing demand for monoclonal antibody drugs due their high efficacy and safety profiles compared with other drug types. The tumor application segment is expected to account for the largest share of the global generic and biosimilar pharmaceuticals market in 2018.
Product Definition:
Generic and biosimilar drugs are both versions of prescription medications, but they differ in a few ways. generics are made to match the active ingredient, dosage form, and strength of the original drug. Biosimilars are similar to generics but must also undergo additional testing to prove that they’re safe and effective. Both generics and biosimilars offer patients an affordable alternative to brand-name drugs.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules, which are manufactured by the human body. There is a wide range of monoclonal antibodies available in the market, which caters to various applications such as cancer treatment and blood purification. Some of the common types of monoclonal antibody products include therapeutic and diagnostic mAbs. Therapeutic mAbs find application in oncology, inflammation & autoimmune diseases; cardiovascular diseases; respiratory disorders; infectious disease diagnosis & vaccines etc.
Interferon:
Interferons are a class of pharmaceutical drugs that are used to treat multiple sclerosis, cancer, and some viral diseases. Interferon is a type of cytokine which is made in the body as well as acquired from outside sources. Cytokines are proteins that regulate and control the immune system by communicating with cells in the immune system (T-cell). They act like hormones to certain cells or groups of cells within the body.
Application Insights:
The tumor application segment led the market in 2017 and is anticipated to witness substantial growth over the forecast period. Tumor biosimilars have shown encouraging results in clinical trials and are being widely used for cancer treatment, which is expected to drive their demand over the coming years.
Insulin was one of the prominent products under tumor category in 2017 owing to its high therapeutic value across various disorders. Moreover, increasing awareness about type-2 diabetes has increased demand for insulin analogues or biosimilars with higher efficiency levels that are likely to propel industry growth during next seven years. In addition, growing usage of insulin as a tool for controlling blood sugar levels among patients suffering from diabetes mellitus is expected to further fuel industry expansion during this period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biopharmaceutical manufacturers coupled with high R&D investment by these companies is one of the major factors contributing to North America’s dominance. In addition, increasing government funding for cancer research and development as well as rising prevalence of cancer is expected to drive this regional market over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increasing healthcare expenditure, growing population base, and improving economic conditions in emerging countries such as China and India. In addition, favorable regulatory reforms are also likely to contribute toward this regional market growth over the next eight years.
Growth Factors:
- Increasing incidence of chronic diseases: The prevalence of chronic diseases is increasing at an alarming rate across the globe. This is primarily because of the changing lifestyle and dietary habits of people. The rise in geriatric population, who are more susceptible to chronic diseases, is also contributing to the growth of this market.
- Growing demand for affordable healthcare: There is a growing demand for affordable healthcare solutions across the world. This has led to an increase in the adoption of generic and biosimilar pharmaceuticals products by consumers and healthcare providers alike.
- Technological advancements: The pharmaceutical industry is witnessing rapid advancements in technology, which is helping manufacturers develop better quality generic and biosimilar drugs at lower costs. This is aiding the growth of this market significantly.
Scope Of The Report
Report Attributes
Report Details
Report Title
Generic and Biosimilar Pharmaceuticals Market Research Report
By Type
Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other
By Application
Tumor, Diabetes, Cardiovascular, Hemophilia, Other
By Companies
Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, 3sbio, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
206
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Generic and Biosimilar Pharmaceuticals Market Report Segments:
The global Generic and Biosimilar Pharmaceuticals market is segmented on the basis of:
Types
Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tumor, Diabetes, Cardiovascular, Hemophilia, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
Highlights of The Generic and Biosimilar Pharmaceuticals Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Other
- By Application:
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Generic and Biosimilar Pharmaceuticals Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Generic and biosimilar pharmaceuticals are medications that are made to look, feel, and work the same as brand-name medications but are cheaper to produce.
Some of the key players operating in the generic and biosimilar pharmaceuticals market are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, 3sbio, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee.
The generic and biosimilar pharmaceuticals market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Generic and Biosimilar Pharmaceuticals Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Generic and Biosimilar Pharmaceuticals Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Generic and Biosimilar Pharmaceuticals Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Generic and Biosimilar Pharmaceuticals Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Generic and Biosimilar Pharmaceuticals Market Size & Forecast, 2018-2028
4.5.1 Generic and Biosimilar Pharmaceuticals Market Size and Y-o-Y Growth
4.5.2 Generic and Biosimilar Pharmaceuticals Market Absolute $ Opportunity
Chapter 5 Global Generic and Biosimilar Pharmaceuticals Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Generic and Biosimilar Pharmaceuticals Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Interferon
5.2.3 Erythropoietin
5.2.4 Insulin
5.2.5 Vaccines
5.2.6 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Generic and Biosimilar Pharmaceuticals Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Generic and Biosimilar Pharmaceuticals Market Size Forecast by Applications
6.2.1 Tumor
6.2.2 Diabetes
6.2.3 Cardiovascular
6.2.4 Hemophilia
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Generic and Biosimilar Pharmaceuticals Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Generic and Biosimilar Pharmaceuticals Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Generic and Biosimilar Pharmaceuticals Analysis and Forecast
9.1 Introduction
9.2 North America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Interferon
9.6.3 Erythropoietin
9.6.4 Insulin
9.6.5 Vaccines
9.6.6 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Applications
9.10.1 Tumor
9.10.2 Diabetes
9.10.3 Cardiovascular
9.10.4 Hemophilia
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Generic and Biosimilar Pharmaceuticals Analysis and Forecast
10.1 Introduction
10.2 Europe Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Generic and Biosimilar Pharmaceuticals Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Interferon
10.6.3 Erythropoietin
10.6.4 Insulin
10.6.5 Vaccines
10.6.6 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Generic and Biosimilar Pharmaceuticals Market Size Forecast by Applications
10.10.1 Tumor
10.10.2 Diabetes
10.10.3 Cardiovascular
10.10.4 Hemophilia
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Generic and Biosimilar Pharmaceuticals Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Generic and Biosimilar Pharmaceuticals Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Interferon
11.6.3 Erythropoietin
11.6.4 Insulin
11.6.5 Vaccines
11.6.6 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Generic and Biosimilar Pharmaceuticals Market Size Forecast by Applications
11.10.1 Tumor
11.10.2 Diabetes
11.10.3 Cardiovascular
11.10.4 Hemophilia
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Generic and Biosimilar Pharmaceuticals Analysis and Forecast
12.1 Introduction
12.2 Latin America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Interferon
12.6.3 Erythropoietin
12.6.4 Insulin
12.6.5 Vaccines
12.6.6 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Applications
12.10.1 Tumor
12.10.2 Diabetes
12.10.3 Cardiovascular
12.10.4 Hemophilia
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Generic and Biosimilar Pharmaceuticals Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Generic and Biosimilar Pharmaceuticals Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Interferon
13.6.3 Erythropoietin
13.6.4 Insulin
13.6.5 Vaccines
13.6.6 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Generic and Biosimilar Pharmaceuticals Market Size Forecast by Applications
13.10.1 Tumor
13.10.2 Diabetes
13.10.3 Cardiovascular
13.10.4 Hemophilia
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Generic and Biosimilar Pharmaceuticals Market: Competitive Dashboard
14.2 Global Generic and Biosimilar Pharmaceuticals Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Amgen
14.3.3 AbbVie
14.3.4 Sanofi-Aventis
14.3.5 Johnson & Johnson
14.3.6 Pfizer
14.3.7 Novo Nordisk
14.3.8 Eli Lilly
14.3.9 Novartis
14.3.10 Merck
14.3.11 3sbio
14.3.12 Changchun High Tech
14.3.13 CP Guojian
14.3.14 Biotech
14.3.15 Gelgen
14.3.16 Innovent
14.3.17 Dong Bao
14.3.18 Ganlee
